CR20220587A - Formulaciones farmacéuticas - Google Patents
Formulaciones farmacéuticasInfo
- Publication number
- CR20220587A CR20220587A CR20220587A CR20220587A CR20220587A CR 20220587 A CR20220587 A CR 20220587A CR 20220587 A CR20220587 A CR 20220587A CR 20220587 A CR20220587 A CR 20220587A CR 20220587 A CR20220587 A CR 20220587A
- Authority
- CR
- Costa Rica
- Prior art keywords
- pharmaceutical formulations
- formulations
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063014923P | 2020-04-24 | 2020-04-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20220587A true CR20220587A (es) | 2023-01-09 |
Family
ID=75674831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20220587A CR20220587A (es) | 2020-04-24 | 2022-11-18 | Formulaciones farmacéuticas |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US12453729B2 (es) |
| EP (1) | EP4138787A1 (es) |
| JP (1) | JP7719796B2 (es) |
| KR (1) | KR20230005270A (es) |
| CN (1) | CN115443128A (es) |
| AR (1) | AR121922A1 (es) |
| AU (1) | AU2021260109B2 (es) |
| BR (1) | BR112022021089A2 (es) |
| CA (1) | CA3179912A1 (es) |
| CL (1) | CL2022002898A1 (es) |
| CO (1) | CO2022016378A2 (es) |
| CR (1) | CR20220587A (es) |
| DO (1) | DOP2022000228A (es) |
| IL (1) | IL297218A (es) |
| MX (1) | MX2022013258A (es) |
| PE (1) | PE20221838A1 (es) |
| PH (1) | PH12022552755A1 (es) |
| TW (1) | TWI893107B (es) |
| WO (1) | WO2021214254A1 (es) |
| ZA (1) | ZA202212663B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12558428B2 (en) | 2024-03-08 | 2026-02-24 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and their use in treating disease |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4555547B2 (ja) | 2000-08-10 | 2010-10-06 | ファイザー イタリア ソシエタ ア レスポンサビリタ リミタータ | キナーゼ阻害剤としての二環式ピラゾール、それらを製造するための方法およびそれらを含む医薬組成物 |
| GB0129117D0 (en) * | 2001-12-05 | 2002-01-23 | Glaxo Group Ltd | Pharmaceutical composition |
| JP2005523276A (ja) | 2002-02-14 | 2005-08-04 | グラクソ グループ リミテッド | Ｎ−［（１−ｎ−ブチル−４−ピペリジニル）メチル］−３，４−ジヒドロ−２ｈ−［１，３］オキサジノ［３，２−ａ］インドール−１０−カルボキシアミド（ｓｂ２０７２６６）またはその塩および乾燥造粒操作を含む方法 |
| KR101159617B1 (ko) * | 2003-10-15 | 2012-06-27 | 후지카가쿠고교가부시키가이샤 | 구강내 속붕해성 정제 |
| JP3841804B2 (ja) * | 2003-10-15 | 2006-11-08 | 富士化学工業株式会社 | 口腔内速崩壊性錠剤用の組成物 |
| WO2006101434A1 (en) | 2005-03-22 | 2006-09-28 | Astrazeneca Ab | NOVEL TETRAHYDRO-1H-PYRIDO [4,3-b] INDOLE DERIVATIVES AS CB1’ RECEPTOR LIGANDS |
| FR2884252B1 (fr) | 2005-04-08 | 2007-05-18 | Aventis Pharma Sa | Nouveaux derives d'isoindoles, compositions les contenant, leur preparation et leurs utilisations pharmaceutiques notamment en tant qu'inhibiteurs d'activites de la proteine chaperone hsp90 |
| GB0523810D0 (en) * | 2005-11-23 | 2006-01-04 | Astrazeneca Ab | Pharmaceutical compositions |
| AR058223A1 (es) | 2005-11-25 | 2008-01-23 | Palau Pharma Sa | Un comuesto de derivados de pirazoloisoquinolina, un procedimiento para l a preparacion de dicho compuesto y una composicion farmaceutica que comprende dicho compuesto |
| EP2223925A1 (en) | 2006-10-09 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| US8377995B2 (en) * | 2007-11-21 | 2013-02-19 | Dainippon Sumitomo Pharma Co., Ltd. | Orally disintegrating tablet |
| US20120157402A1 (en) | 2009-05-27 | 2012-06-21 | Liangxian Cao | Methods for treating brain tumors |
| HUE052510T2 (hu) | 2009-05-27 | 2021-05-28 | Ptc Therapeutics Inc | Módszerek a rák és a nem daganatos állapotok kezelésére |
| WO2010138695A1 (en) | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating neurofibromatosis |
| TW201129386A (en) * | 2009-11-05 | 2011-09-01 | Fmc Corp | Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients |
| TWI461213B (zh) * | 2009-11-05 | 2014-11-21 | Fmc Corp | 作為藥物賦形劑之微晶纖維素及磷酸鈣之組合物 |
| DK3150610T3 (da) * | 2010-02-12 | 2019-11-04 | Pfizer | Salte og polymorfer af 8-fluor-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-on |
| HUE033581T2 (hu) | 2010-06-10 | 2017-12-28 | Seragon Pharmaceuticals Inc | Ösztrogén receptor modulátorok és alkalmazásaik |
| US8853423B2 (en) | 2010-06-17 | 2014-10-07 | Seragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
| JP5656258B2 (ja) * | 2011-03-09 | 2015-01-21 | 塩野義製薬株式会社 | ガランタミンを含有する口腔内崩壊錠剤 |
| SG11201403002RA (en) | 2011-12-14 | 2014-07-30 | Seragon Pharmaceuticals Inc | Fluorinated estrogen receptor modulators and uses thereof |
| RU2647421C2 (ru) | 2012-12-27 | 2018-03-15 | Зентива Саглык Урунлеры Сан. Ве Тыдж. А.Ш. | Способ сухого гранулирования для получения композиций метформина в виде таблеток и его композиции |
| RU2644769C2 (ru) | 2013-01-23 | 2018-02-14 | Астразенека Аб | Химические соединения |
| PE20160874A1 (es) | 2013-05-28 | 2016-09-04 | Astrazeneca Ab | Compuestos quimicos |
| MX2015016171A (es) | 2013-06-19 | 2016-08-08 | Seragon Pharmaceuticals Inc | Moduladores del receptor de estrogeno de azetidina y usos de los mismos. |
| WO2014205138A1 (en) | 2013-06-19 | 2014-12-24 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulator and uses thereof |
| WO2015092634A1 (en) | 2013-12-16 | 2015-06-25 | Novartis Ag | 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders |
| CN117865872A (zh) | 2014-12-18 | 2024-04-12 | 豪夫迈·罗氏有限公司 | 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途 |
| JP2017538727A (ja) | 2014-12-18 | 2017-12-28 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 癌の治療に有用な２，３−ジフェニルクロメンの誘導体 |
| CN107406424B (zh) | 2014-12-18 | 2020-08-25 | 豪夫迈·罗氏有限公司 | 雌激素受体调节剂及其用途 |
| WO2016174551A1 (en) | 2015-04-27 | 2016-11-03 | Pfizer Inc. | Anti-estrogenic compounds |
| EP3303326B1 (en) | 2015-05-26 | 2020-12-16 | H. Hoffnabb-La Roche Ag | Heterocyclic estrogen receptor modulators and uses thereof |
| KR20180012853A (ko) | 2015-06-16 | 2018-02-06 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 피페리딘 유도체 및 이의 제조 방법 및 약학적 용도 |
| CN106518768B (zh) | 2015-09-15 | 2021-07-02 | 江苏恒瑞医药股份有限公司 | 丙烯酸类衍生物、其制备方法及其在医药上的应用 |
| DK3355884T3 (da) | 2015-10-01 | 2021-08-02 | Olema Pharmaceuticals Inc | Tetrahydro-1h-pyrido[3,4-b]indol-antiøstrogenlægemidler |
| CN108349952A (zh) | 2015-11-09 | 2018-07-31 | 豪夫迈·罗氏有限公司 | 四氢萘雌激素受体调节剂及其用途 |
| CA3011391C (en) | 2015-11-12 | 2021-02-09 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Acrylic acid derivative, preparation method and use in medicine thereof |
| HK1244808A1 (zh) | 2015-12-22 | 2018-08-17 | 江苏恒瑞医药股份有限公司 | 苯并哌啶类衍生物、其制备方法及其在医药上的应用 |
| US9969732B2 (en) | 2016-04-08 | 2018-05-15 | Genentech, Inc. | Tetrahydroisoquinoline estrogen receptor modulators and uses thereof |
| US10125135B2 (en) | 2016-04-20 | 2018-11-13 | Astrazeneca Ab | Chemical compounds |
| CN109415388A (zh) | 2016-05-06 | 2019-03-01 | 路易斯安那泽维尔大学 | 选择性雌激素受体下调剂(serds) |
| CN109415361B (zh) | 2016-06-29 | 2022-03-08 | 浙江海正药业股份有限公司 | 丙烯酸类衍生物及其制备方法和其在医药上的用途 |
| US10149839B2 (en) | 2016-07-25 | 2018-12-11 | Astrazeneca Ab | Chemical compounds |
| CN107814798B (zh) | 2016-09-14 | 2020-11-03 | 四川科伦博泰生物医药股份有限公司 | 3-取代丙烯酸类化合物及其制备方法和用途 |
| ES2975558T3 (es) | 2016-09-15 | 2024-07-09 | Arvinas Inc | Derivados de indol como degradantes de receptor de estrógeno |
| BR102016024814A2 (pt) | 2016-10-24 | 2018-05-08 | Aché Laboratórios Farmacêuticos S.A. | composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono |
| JOP20190090B1 (ar) * | 2016-10-24 | 2023-03-28 | Astrazeneca Ab | مشتقات 9،8،7،6-رابع هيدرو-3h-بيرازولو [4،3-f]أيزوكينولين مفيدة في علاج السرطان |
| US20200077658A1 (en) | 2016-12-16 | 2020-03-12 | Basf Se | Pesticidal Compounds |
| PH12019501328B1 (en) | 2016-12-16 | 2023-05-12 | Lilly Co Eli | 7-phenylethlamino-4h-pyrimido][4,5-d][1,3] oxazin-2-one compounds as mutant 1dh1 and 1dh2 inhibitors |
| JOP20190144A1 (ar) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
| TWI831738B (zh) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物 |
| JP7291077B2 (ja) | 2016-12-16 | 2023-06-14 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｊａｋファミリーのキナーゼの低分子阻害物質 |
| CN110325530B (zh) | 2016-12-16 | 2022-01-11 | 辉瑞大药厂 | Glp-1受体激动剂及其用途 |
| GEP20207202B (en) | 2017-01-30 | 2020-12-25 | Chiesi Farm Spa | Tyrosine amide derivatives as rho-kinase inhibitors |
| CN108815125A (zh) * | 2018-07-23 | 2018-11-16 | 深圳市优普惠药品股份有限公司 | 微晶纤维素与无水磷酸氢钙复合物及其制备工艺 |
-
2021
- 2021-04-22 MX MX2022013258A patent/MX2022013258A/es unknown
- 2021-04-22 PH PH1/2022/552755A patent/PH12022552755A1/en unknown
- 2021-04-22 AU AU2021260109A patent/AU2021260109B2/en active Active
- 2021-04-22 BR BR112022021089A patent/BR112022021089A2/pt unknown
- 2021-04-22 PE PE2022002453A patent/PE20221838A1/es unknown
- 2021-04-22 EP EP21721483.2A patent/EP4138787A1/en active Pending
- 2021-04-22 US US17/237,201 patent/US12453729B2/en active Active
- 2021-04-22 CA CA3179912A patent/CA3179912A1/en active Pending
- 2021-04-22 KR KR1020227040916A patent/KR20230005270A/ko active Pending
- 2021-04-22 WO PCT/EP2021/060591 patent/WO2021214254A1/en not_active Ceased
- 2021-04-22 IL IL297218A patent/IL297218A/en unknown
- 2021-04-22 CN CN202180030163.2A patent/CN115443128A/zh active Pending
- 2021-04-22 JP JP2022563999A patent/JP7719796B2/ja active Active
- 2021-04-23 TW TW110114700A patent/TWI893107B/zh active
- 2021-04-23 AR ARP210101092A patent/AR121922A1/es unknown
-
2022
- 2022-10-20 CL CL2022002898A patent/CL2022002898A1/es unknown
- 2022-10-21 DO DO2022000228A patent/DOP2022000228A/es unknown
- 2022-11-15 CO CONC2022/0016378A patent/CO2022016378A2/es unknown
- 2022-11-18 CR CR20220587A patent/CR20220587A/es unknown
- 2022-11-21 ZA ZA2022/12663A patent/ZA202212663B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US12453729B2 (en) | 2025-10-28 |
| CN115443128A (zh) | 2022-12-06 |
| TWI893107B (zh) | 2025-08-11 |
| AR121922A1 (es) | 2022-07-27 |
| EP4138787A1 (en) | 2023-03-01 |
| BR112022021089A2 (pt) | 2022-12-06 |
| JP7719796B2 (ja) | 2025-08-06 |
| MX2022013258A (es) | 2022-11-14 |
| KR20230005270A (ko) | 2023-01-09 |
| AU2021260109B2 (en) | 2024-07-11 |
| DOP2022000228A (es) | 2022-11-30 |
| TW202206074A (zh) | 2022-02-16 |
| PH12022552755A1 (en) | 2024-03-25 |
| PE20221838A1 (es) | 2022-11-29 |
| CO2022016378A2 (es) | 2022-11-29 |
| AU2021260109A1 (en) | 2022-12-15 |
| US20210330665A1 (en) | 2021-10-28 |
| ZA202212663B (en) | 2023-07-26 |
| CA3179912A1 (en) | 2021-10-28 |
| JP2023522247A (ja) | 2023-05-29 |
| CL2022002898A1 (es) | 2023-06-02 |
| WO2021214254A1 (en) | 2021-10-28 |
| IL297218A (en) | 2022-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4045480A4 (en) | PHARMACEUTICAL FORMULATIONS | |
| EP4221690A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| IL285674A (en) | Pharmaceutical formulations | |
| EP4135699A4 (en) | Pharmaceutical compositions | |
| SI3927315T1 (sl) | Okusne formulacije | |
| EP3746080A4 (en) | PHARMACEUTICAL FORMULATIONS | |
| EP3914234A4 (en) | Pharmaceutical compositions | |
| DK3908321T3 (da) | Farmaceutisk sammensætning | |
| EP4125430A4 (en) | SWEETENER FORMULATIONS | |
| DK4027973T3 (da) | Formuleringer til lægemiddeladministration | |
| EP4434969A4 (en) | ANTI-SARS-CoV-2 MEDICATION | |
| DK4279082T3 (da) | Formuleringer | |
| EP4284362A4 (en) | Formulations | |
| EP4387657A4 (en) | Lipid nanoparticle formulations | |
| EP4099999C0 (en) | DOCETAXEL FORMULATIONS | |
| PL3787596T3 (pl) | Ulepszone formulacje farmaceutyczne | |
| PT3949952T (pt) | Composição farmacêutica | |
| IL310652A (en) | Formulations of radiprodil | |
| EP4479041A4 (en) | MULTIMERIZATION PHARMACEUTICAL COMPOSITIONS | |
| EP3651800C0 (en) | HYDROCOMPRESSED PHARMACEUTICAL FORMULATIONS | |
| EP4188088A4 (en) | Formulations | |
| EP4175676A4 (en) | MUCO-PENETRATING FORMULATIONS | |
| EP4349366A4 (en) | PHARMACEUTICAL COMPOSITION | |
| EP4268830A4 (en) | PHARMACEUTICAL COMPOSITION | |
| EP4265252A4 (en) | Pharmaceutical composition |